Reviewing Zeltiq Aesthetics (ZLTQ) & Harvard Bioscience (HBIO)

Zeltiq Aesthetics (NASDAQ: ZLTQ) and Harvard Bioscience (NASDAQ:HBIO) are both advanced medical equipment & technology – nec companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

61.7% of Harvard Bioscience shares are held by institutional investors. 15.6% of Zeltiq Aesthetics shares are held by insiders. Comparatively, 9.8% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Zeltiq Aesthetics and Harvard Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zeltiq Aesthetics 9.78% 31.74% 20.11%
Harvard Bioscience -3.16% 1.11% 0.76%

Valuation and Earnings

This table compares Zeltiq Aesthetics and Harvard Bioscience’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zeltiq Aesthetics N/A N/A N/A ($0.03) -1,882.67
Harvard Bioscience $104.52 million 1.32 -$4.30 million ($0.09) -43.89

Zeltiq Aesthetics has higher earnings, but lower revenue than Harvard Bioscience. Zeltiq Aesthetics is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zeltiq Aesthetics and Harvard Bioscience, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zeltiq Aesthetics 0 8 1 0 2.11
Harvard Bioscience 0 0 0 0 N/A

Zeltiq Aesthetics presently has a consensus target price of $56.25, suggesting a potential downside of 0.41%. Given Zeltiq Aesthetics’ higher possible upside, equities analysts clearly believe Zeltiq Aesthetics is more favorable than Harvard Bioscience.

Summary

Zeltiq Aesthetics beats Harvard Bioscience on 7 of the 10 factors compared between the two stocks.

Zeltiq Aesthetics Company Profile

ZELTIQ Aesthetics, Inc. is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system. CoolSculpting is a non-invasive fat reduction procedure. CoolSculpting utilizes its controlled cooling technology to selectively reduce stubborn fat bulges. The CoolSculpting system includes CoolSculpting control unit and CoolSculpting applicators. The CoolSculpting Applicator delivers vacuum suction and cooling to the fat bulge being treated.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

Receive News & Ratings for Zeltiq Aesthetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.